• Gilead signs drug discovery deal with Second Genome pharmaceutical-technology
    April 08, 2020
    Gilead Sciences has entered a multi-programme agreement with Second Genome to discover targets and drug candidates for inflammatory bowel disease (IBD) treatment.
  • Second Genome Doses First Patient in SGM-1019 Study americanpharmaceuticalreview
    January 24, 2019
PharmaSources Customer Service